Developing a new drug to protect the brain after cardiac arrest
Official title: IND-enabling studies for a potent and efficient neuroprotective drug
Funded at Neurexis Therapeutics, INC. · NIH-10921077 · Data updated 2026-11-12
This study is testing a new drug designed to help protect the brain after a cardiac arrest, and it's for people who want to see better recovery outcomes after such an event.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Neurexis Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Aurora, United States) |
| Project start | September 24, 2021 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $938,239 |
| NIH project number | 2R44NS120427-02A1 |
| Project ID | NIH-10921077 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have suffered a cardiac arrest and are at risk of global cerebral ischemia.
✕Less likely to help
Patients who have not experienced cardiac arrest or those with conditions unrelated to global cerebral ischemia may not benefit from this research.
What this research studies
This research focuses on creating a new neuroprotective drug aimed at treating global cerebral ischemia (GCI), a condition that can occur after cardiac arrest. The drug, an optimized peptide inhibitor called tatCN19o, has shown promising results in animal models that simulate human cardiac arrest scenarios. By administering this drug in conjunction with therapeutic hypothermia, researchers aim to significantly reduce brain cell death and improve recovery outcomes. The study involves rigorous testing to ensure the drug's effectiveness and safety before it can be used in humans.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that significantly improves recovery and reduces cognitive impairment in patients who experience cardiac arrest.
How similar studies have gone: Previous studies have shown success with similar neuroprotective strategies in animal models, indicating potential for effective human applications.
Where this research is happening
-
Neurexis Therapeutics, INC.
Aurora, United States Active
Researchers
- Principal investigator: Goforth, Robyn L — Neurexis Therapeutics, INC.
- Study coordinator: Goforth, Robyn L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.